File 027074
Female Health Company FC2 Female Condom Funding Proposal and Market Analysis (File 027074)
Comprehensive business and public health case for FC2 female condom procurement, detailing funding gaps created by U.S. policy changes and international health benefits across multiple markets.
Summary
This document presents the Female Health Company's fundraising proposal for FC2 female condoms, highlighting how decreased UNFPA funding due to U.S. policy changes has created stockouts in 10 African and Latin American countries. The proposal includes market analysis showing female condoms represent only 3-6% of the condom market despite high demand, clinical evidence of user satisfaction, economic return-on-investment data from Kenya and Nigeria, and rebuttals to common misconceptions about cost, demand, and product acceptance among both men and women.
The case for the FC2 female condom the female health company
Overview
• Commodity Context• Contextual overview• Debunking myths through evidence
www.femalecondom.comGet Inspired
https://fc2femalecondom.com/get-inspired/https://youtu.be/O0V-KYyTza8
ASKDue to the funding decrease UNFPA is experiencing as the US pulled all their funding under president Trump, and the European countries have re-directed their funding to deal with the migrant influx, there is a funding shortfall leading to Female Condom stock outs in countries.
The Female Health Company is looking for donors who are willing to donate money to UNFPA, and earmark that money for purchase of the FC2 female condom only, so that they can purchase the FC2 female condom for the following countries:Uganda : 3 million units Ghana: 1 million unitsBotswana: 1 million units Tunesia: 1 million unitsSierra Leone: 500,000 units Bolivia: 500,000 unitsTanzania: 1 million units Haiti: 500,000 unitsEthiopia: 1 million units Congo DR: 2 million units
The Female Health Company provides the FC2 female condom.
FC2 is the only product currently available:
▪ Under a women’s control▪ Offering triple protection: ▪ Against HIV/AIDS ▪ STIs (as well as ZIKA) ▪ Unplanned pregnancy▪ Approved by the FDA and WHO, as well as other international and national health agencies
5
Widest possible choiceFC2 falls under Reproductive Health Supply commodities with UNFPA Supplies:
• Contraceptives- Combined low dose OC Pills - Implantable Contraceptives- Emergency Contraceptives - Injectable Contraceptives- Female Condoms - Intrauterine Device (IUD)- Lubricants - Male Condoms- Progestogen only Pills
• Diagnostic Test Kits• Kits• Medical Devices• Pharmaceutical Devices
Male and female condom marketsMale Condom Market Global Public sector: 10 billionMale Condom Market FP2020, 69 countries: 1-1,6 billionFemale Condom Market: 30-60 millionFC is 3%-6% of FP2020 condom market and 0,3%-0,6% of global condom market
Customers and DistributionKey purchasers:▪ Global agencies
▪ Government/ Ministries of Health▪ State and local health departments/agencies▪ NGOs and CBOs/IPPF/MSI▪ Distributors who hold registration for FC2▪ Social marketing organizations such as PSI and DKT▪ Commercial partners that promote to consumers
Why Female condoms?The female condom is the only female initiated method that provides triple protection against STIs including HIV and Zika and against unplanned pregnancyIntroduction of male and female condoms in the same market leads to more overall protected sex actsCost effective, positive return on investment
HIV/AIDS global overview• No. 1 cause of death globally for women age 15-44• 80% of female cases contracted via heterosexual transmission• Male and female condoms are the only prevention products available
Worldwide, women represent >50% of new Adult HIV/AIDS infections
The social case for FC2Empowering women as a development tool by decreasing maternal mortality & fewer unwanted pregnancies and protecting from HIV-infection, and other STIs
▪ Worldwide 215 million women who like to plan or limit number of children have no access to contraception ▪ Worldwide 21.6 million unsafe abortions cause 5 million women hospitalized each year, and account for 13 % of maternal deaths ▪ Worldwide women and girls account for slightly more than half of all HIV infections ▪ In sub-Saharan Africa 23 million people live with HIV/AIDS: over 12 million are women and nearly 2.5 million are children
The product case for fc2Only FDA and WHO approved Female Condom and as a result approved for bulk procurement by UNFPA and USAIDThe strong preference for FC2 due to its non allergenic material nitrile and long standing reputationFC2 is has been distributed to 144 countries.The backup support, materials, training provided by FHC
The product case for fc2 (2)5) The FC2 female condom, as opposed to the latex male condom, is made out of Nitrile which holds many benefits:- Three times stronger than latex,- Can be used by people who are latex sensitive, or allergic- Can hold both water and oil based lubricants (latex tears with oil)- Can be inserted hours in advance- Transfers body heat ensuring a more natural sensation
6) The FC2 is hormone free, which means that it does not have the side effects of some hormone based contraceptives.
7) Preferable alternative to a male condom, according to males▪ Men don’t have to wear it▪ Not tight/restricting▪ Can be inserted in advance of sexual activity
Debunking myths & MisconceptionsCertain Myths and Misconceptions among decision still exist today, even though the evidence tells otherwise
It is too expensiveThere is no demandWe already have male condoms and LARCs so the FC is not necessaryMen do not like the product, and without them it will never succeed
1) It is too Expensive: false “The Business Case for Female Condoms” (Global Health Visions, 2014)
Return on investment of female condom procurement for governments through 2 ways:Cost savings to the health system, by focussing on prevention instead of treatmentEconomic productivity losses averted, as more women are able to join the workforce.
The business case for female condoms (2) The Business case for female condoms found that for every $1,- invested in buying female condoms in Kenya a return of $1,94 is made. In Nigeria for every $1,- invested a return of $3,20 is made. See table below for health benefits.
2) There is no demand: FalseUruguay Study, UNFPA Uruguay and MOH Uruguay (2017):- 77% of average women said the FC2 was good or very goodStudy participants cited greater comfort and practicality and greater protection and safety as the two main advantages of the FC2- 81% said they would continue using the FC2 in the future- 64 % said they experienced no difficulties at all
South Africa National Female Condom ProgramEvaluation (2017)- 80% of women feld the FC put them in charge- The level of unprotected sex declined from 43,3 % at baseline to 8,4 % at 12 months after the introduction of the FC
3) We already have other commodities: FalseAIGHD Research on the Female Condom in Mozambique (2017) The increase in female condom use was not accompanied by an off-setting decrease in ever or current use of alternative methods. If anything, current use of male condoms and other modern contraceptives increased slightly in the treatment group. Female condoms thus seemed to complement the existing choice set of regular contraceptives
South Africa National Female Condom Program Evaluation (2017) Of the current FC users 73,4% reported using condoms in general more often than before they started using the female condom.
4) Men do not like the product: falseSouth Africa National Female Condom Program Evaluation (2017)
- At their one month interview 58% of men said that the FC was better or much better than the MC and at 12 months this rose to 74%- At six months into the research 97% of women reported that their partners were supportive of using the FC
In summaryFemale Condoms provide a return on investmentFemale Condoms are in high demand with both men and women, average and key populationsFemale Condoms increase the overall use of barrier methods and contraceptives, enforcing decrease in overall number of unprotected sex acts
oleObject1.bin
Chart1
FemaleMale 0.52 0.48
Sheet1
Column1Female 52%Male 48% To resize chart data range, drag lower right corner of range.
Column152%Female48%Male
image14.emf
52%Female 48%Male
image16.emf
1,000,000 femalecondoms Cameroon Kenya Myanmar Nigeria# DALYs averted 9,292 9,713 4,122 9,488# of unintendedpregnanciesaverted 1,939 1,939 1,939 1,939#of HIV infectionsaverted 108 125 62 100#of maternaldeaths averted 8 4 2 7#of infant deathsaverted 53 39 14 77#of unsafeabortions averted 243 265 521 213